This study is evaluating the safety and effectiveness of Tildacerfont, compared to placebo, after 12 weeks of treatment in patients with polycystic ovary syndrome or PCOS.
Who can join this trial?
You may be able to join this clinical trial if you:
Are female, 18-40 years old
Have a diagnosis of PCOS
Meet additional screening requirements
Being part of this clinical trial is voluntary.
Eligible participants will receive all study-related care, procedures and medication at no cost. In addition, eligible participants may receive compensation for time and travel. No health insurance is required to participate.
For more information about this study, please call (316) 425-6333.